瑞巴派特灌肠剂——治疗皮质类固醇依赖型或抵抗型溃疡性结肠炎患者的新有效疗法。

Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis.

作者信息

Miyata Mitsuki, Kasugai Kunio, Ishikawa Tetsuya, Kakumu Shinichi, Onishi Masafumi, Mori Takeshi

机构信息

Department of Gastroenterology, Aichi Medical University School of Medicine, Aichi-Gun, Aichi 480-1195, Japan. mmiyata@ aichi-med-u.ac.jp

出版信息

Dig Dis Sci. 2005 Oct;50 Suppl 1:S119-23. doi: 10.1007/s10620-005-2816-1.

DOI:10.1007/s10620-005-2816-1

PMID:16184413

Abstract

In this study we investigated the effect of rebamipide enema in patients with steroid-resistant and/or dependent ulcerative colitis. Rebamipide enemas were administered twice daily for a 12-week period; this treatment was further continued longer in patients who requested this. Disease activity index as reflecting the clinical condition and endoscopic index with histological grading were determined before and after the treatment period. Nine of 11 (81.8%) patients on 12-week treatment with rebamipide approved and were classified as colitis in remission. Moreover, seven of 11 patients requested long-term medication, the longest medication term being 80 weeks. These results medicated that rebamipide enemas may be effective in patients with steroid-resistant and/or dependent ulcerative colitis.

摘要

在本研究中，我们调查了瑞巴派特灌肠剂对激素抵抗型和/或激素依赖型溃疡性结肠炎患者的疗效。瑞巴派特灌肠剂每天给药两次，持续12周；对有此需求的患者，该治疗会进一步持续更长时间。在治疗期前后测定反映临床状况的疾病活动指数以及带有组织学分级的内镜指数。11名接受瑞巴派特12周治疗的患者中有9名（81.8%）病情得到改善并被归类为缓解期结肠炎。此外，11名患者中有7名要求长期用药，最长用药期限为80周。这些结果表明，瑞巴派特灌肠剂可能对激素抵抗型和/或激素依赖型溃疡性结肠炎患者有效。